0000749647 2025-01-01 2025-09-30 0000749647 2025-11-10 0000749647 2025-09-30 0000749647 2024-12-31 0000749647 2025-07-01 2025-09-30 0000749647 2024-07-01 2024-09-30 0000749647 2024-01-01 2024-09-30 0000749647 2023-12-31 0000749647 2024-09-30 0000749647 us-gaap:CommonStockMember 2025-06-30 0000749647 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000749647 us-gaap:TreasuryStockCommonMember 2025-06-30 0000749647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0000749647 us-gaap:RetainedEarningsMember 2025-06-30 0000749647 2025-06-30 0000749647 us-gaap:CommonStockMember 2024-06-30 0000749647 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000749647 us-gaap:TreasuryStockCommonMember 2024-06-30 0000749647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000749647 us-gaap:RetainedEarningsMember 2024-06-30 0000749647 2024-06-30 0000749647 us-gaap:CommonStockMember 2024-12-31 0000749647 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000749647 us-gaap:TreasuryStockCommonMember 2024-12-31 0000749647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000749647 us-gaap:RetainedEarningsMember 2024-12-31 0000749647 us-gaap:CommonStockMember 2023-12-31 0000749647 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000749647 us-gaap:TreasuryStockCommonMember 2023-12-31 0000749647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000749647 us-gaap:RetainedEarningsMember 2023-12-31 0000749647 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000749647 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000749647 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0000749647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0000749647 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0000749647 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000749647 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000749647 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0000749647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000749647 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000749647 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0000749647 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0000749647 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-09-30 0000749647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-09-30 0000749647 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0000749647 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000749647 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0000749647 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-09-30 0000749647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0000749647 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0000749647 us-gaap:CommonStockMember 2025-09-30 0000749647 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0000749647 us-gaap:TreasuryStockCommonMember 2025-09-30 0000749647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0000749647 us-gaap:RetainedEarningsMember 2025-09-30 0000749647 us-gaap:CommonStockMember 2024-09-30 0000749647 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000749647 us-gaap:TreasuryStockCommonMember 2024-09-30 0000749647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000749647 us-gaap:RetainedEarningsMember 2024-09-30 0000749647 2025-08-07 2025-08-07 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:OvationTwoAndMRDTrialsMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:OvationTwoAndMRDTrialsMember 2024-01-01 2024-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:OvationThreeMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:OvationThreeMember 2024-01-01 2024-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:PlaccineVaccineMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:PlaccineVaccineMember 2024-01-01 2024-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:OtherClinicalAndRegulatoryMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember IMNN:OtherClinicalAndRegulatoryMember 2024-01-01 2024-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:ClinicalResearchMember 2024-01-01 2024-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:NonClinicalRAndDAndCMCMember IMNN:OvationMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:NonClinicalRAndDAndCMCMember IMNN:OvationMember 2024-01-01 2024-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:NonClinicalRAndDAndCMCMember IMNN:PlaccineVaccineMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:NonClinicalRAndDAndCMCMember IMNN:PlaccineVaccineMember 2024-01-01 2024-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:NonClinicalRAndDAndCMCMember IMNN:ManufacturingCMCMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:NonClinicalRAndDAndCMCMember IMNN:ManufacturingCMCMember 2024-01-01 2024-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:NonClinicalRAndDAndCMCMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember IMNN:NonClinicalRAndDAndCMCMember 2024-01-01 2024-09-30 0000749647 us-gaap:OperatingSegmentsMember 2025-01-01 2025-09-30 0000749647 us-gaap:OperatingSegmentsMember 2024-01-01 2024-09-30 0000749647 2024-05-15 2024-05-15 0000749647 2025-07-22 2025-07-22 0000749647 2025-06-02 2025-06-02 0000749647 2025-06-02 0000749647 2025-07-25 2025-07-25 0000749647 2025-07-25 0000749647 us-gaap:CommonStockMember 2025-07-25 2025-07-25 0000749647 srt:MaximumMember 2025-07-25 0000749647 srt:MinimumMember 2025-07-25 0000749647 srt:MinimumMember 2025-07-11 0000749647 srt:MaximumMember 2025-07-11 0000749647 2025-07-28 0000749647 srt:MaximumMember 2025-07-28 0000749647 srt:MinimumMember 2025-07-28 0000749647 IMNN:AtTheMarketOfferingAgreementMember 2024-05-15 2024-05-15 0000749647 2024-09-03 2024-09-03 0000749647 IMNN:AtTheMarketOfferingAgreementMember 2025-07-22 2025-07-22 0000749647 IMNN:AtTheMarketOfferingAgreementMember 2025-07-22 0000749647 IMNN:SalesAgreementMember 2025-07-22 2025-07-22 0000749647 IMNN:AtTheMarketOfferingAgreementMember 2024-01-01 2024-12-31 0000749647 IMNN:AtTheMarketOfferingAgreementMember 2025-01-01 2025-09-30 0000749647 us-gaap:SubsequentEventMember IMNN:AtTheMarketOfferingAgreementMember 2025-10-01 2025-11-13 0000749647 IMNN:JulyTwoThousandTwentyFourOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2024-07-30 2024-07-30 0000749647 IMNN:JulyTwoThousandTwentyFourOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2024-07-30 0000749647 us-gaap:WarrantMember IMNN:JulyTwoThousandTwentyFourOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2024-07-30 2024-07-30 0000749647 us-gaap:WarrantMember IMNN:JulyTwoThousandTwentyFourOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2024-07-30 0000749647 IMNN:JulyTwoThousandTwentyFourOfferingMember 2025-05-12 2025-05-12 0000749647 IMNN:JulyTwoThousandTwentyFourOfferingMember 2025-05-12 0000749647 IMNN:MayTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-05-23 2025-05-23 0000749647 IMNN:PreFundedMember IMNN:MayTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-05-23 2025-05-23 0000749647 IMNN:PreFundedMember IMNN:MayTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-05-23 0000749647 us-gaap:WarrantMember IMNN:MayTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-05-23 2025-05-23 0000749647 us-gaap:WarrantMember IMNN:MayTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-05-23 0000749647 IMNN:PlacementAgentsWarrantMember IMNN:MayTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-05-23 2025-05-23 0000749647 IMNN:PlacementAgentsWarrantMember IMNN:MayTwoThousandTwentyFiveOfferingMember IMNN:SecuritiesPurchaseAgreementMember 2025-05-23 0000749647 IMNN:TwoThousandAndEighteenStockIncentivePlanMember 2018-12-31 0000749647 IMNN:TwoThousandAndEighteenStockIncentivePlanMember 2025-09-30 0000749647 IMNN:GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember IMNN:EquityStockAwardsMember 2025-09-30 0000749647 IMNN:TwoThousandEighteenPlanMember IMNN:EquityStockAwardsMember 2025-09-30 0000749647 IMNN:EmployeeStockOptionAndRestrictedStockAwardsMember 2025-01-01 2025-09-30 0000749647 IMNN:EmployeeStockOptionAndRestrictedStockAwardsMember 2024-01-01 2024-09-30 0000749647 IMNN:EmployeeStockOptionAndRestrictedStockAwardsMember us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-09-30 0000749647 IMNN:EmployeeStockOptionAndRestrictedStockAwardsMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0000749647 IMNN:EmployeeStockOptionAndRestrictedStockAwardsMember us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-09-30 0000749647 IMNN:EmployeeStockOptionAndRestrictedStockAwardsMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0000749647 srt:MinimumMember 2025-01-01 2025-09-30 0000749647 srt:MaximumMember 2025-01-01 2025-09-30 0000749647 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0000749647 us-gaap:EmployeeStockOptionMember 2024-12-31 0000749647 us-gaap:RestrictedStockMember 2024-12-31 0000749647 us-gaap:RestrictedStockMember 2025-01-01 2025-09-30 0000749647 us-gaap:EmployeeStockOptionMember 2025-09-30 0000749647 us-gaap:RestrictedStockMember 2025-09-30 0000749647 srt:MinimumMember 2024-01-01 2024-09-30 0000749647 srt:MaximumMember 2024-01-01 2024-09-30 0000749647 IMNN:LawrencevilleNewJerseyLeaseMember 2023-08-31 0000749647 srt:MinimumMember IMNN:LawrencevilleNewJerseyLeaseMember 2023-08-01 2023-08-31 0000749647 srt:MaximumMember IMNN:LawrencevilleNewJerseyLeaseMember 2023-08-01 2023-08-31 0000749647 IMNN:LawrencevilleNewJerseyLeaseMember 2025-04-30 0000749647 srt:ScenarioForecastMember IMNN:LawrencevilleNewJerseyLeaseMember 2026-04-01 0000749647 srt:MinimumMember IMNN:LawrencevilleNewJerseyLeaseMember 2025-04-01 2025-04-30 0000749647 srt:MaximumMember IMNN:LawrencevilleNewJerseyLeaseMember 2025-04-01 2025-04-30 0000749647 IMNN:HuntsvilleAlabamaLeaseMember 2023-01-31 0000749647 srt:MinimumMember IMNN:HuntsvilleAlabamaLeaseMember 2023-01-01 2023-01-31 0000749647 srt:MaximumMember IMNN:HuntsvilleAlabamaLeaseMember 2023-01-01 2023-01-31 iso4217:USD shares iso4217:USD shares utr:sqft IMNN:Segment pure false --12-31 Q3 0000749647 10-Q true 2025-09-30 2025 false 001-15911 Imunon, Inc. DE 52-1256615 997 Lenox Drive Suite 100 Lawrenceville NJ 08648 (609) 896-9100 NA Common stock, par value $0.01 per share IMNN NASDAQ Yes Yes Non-accelerated Filer true false false 3070354 0.01 5250929 5872767 2006756 2136192 7257685 8008959 601425 541272 1078623 1117133 50000 50000 1128623 1167133 8987733 9717364 1126826 1300026 2676951 3033747 394135 452358 4197912 4786131 708097 686935 4906009 5473066 0.01 0.01 100000 100000 0 0 0 0 0.01 0.01 350000000 112500000 2896275 966714 2896273 966712 28963 9667 421213171 411122863 -417075222 -406803044 4166912 4329486 2 2 85188 85188 4081724 4244298 8987733 9717364 1899251 3293209 5291297 9406715 1576577 1668258 5097694 5579549 3475828 4961467 10388991 14986264 -3475828 -4961467 -10388991 -14986264 46704 115992 116813 423247 46704 115992 116813 423247 -3429124 -4845475 -10272178 -14563017 -1.16 -1.16 -3.76 -3.76 -5.53 -5.53 -14.13 -14.13 2943655 2943655 1289823 1289823 1855922 1855922 1030622 1030622 -10272178 -14563017 216830 202938 312805 349892 61983 115895 364177 99040 1280385 -129436 -324580 -841351 -2330958 -10239523 -14433986 57174 9915448 276983 14634 -276983 9843640 6437251 9063715 3467694 10277 9894668 9063715 -621838 4473369 5872767 5838566 5250929 10311935 274295 1717502 17175 416373961 2 -85188 -413646098 2659850 -3429124 -3429124 70448 704 704 543265 5433 3467387 3472820 222227 2223 1497777 1500000 330397 3304 -13581 -10277 10767 108 98932 99040 1667 16 16 -211305 -211305 2896273 28963 421213171 2 -85188 -417075222 4081724 626727 6267 401720499 2 -85188 -397900344 3741234 -4845475 -4845475 339254 3393 9060322 9063715 734 7 103 110 232137 232137 966715 9667 411013061 2 -85188 -402745819 8191721 966712 9667 411122863 2 -85188 -406803044 4244298 -10272178 -10272178 70448 704 704 1032752 10328 6426219 6436547 482550 4826 3462869 3467695 330397 3304 -13581 -10277 10767 108 98932 99040 2647 26 26 115869 115869 2896273 28963 421213171 2 -85188 -417075222 4081724 626654 6266 401588570 2 -85188 60796 -388182802 13387642 626654 6266 401588570 2 -85188 60796 -388182802 13387642 -14563017 -14563017 339254 3393 9060322 9063715 807 8 113 121 -60796 -60796 364056 364056 966715 9667 411013061 2 -85188 -402745819 8191721 966715 9667 411013061 2 -85188 -402745819 8191721 <p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zliTqT9G2TDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1. <span id="xdx_82D_zcxifpBoaL2d">Business Description</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imunon, Inc. (“Imunon” or the “Company”) is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase II clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_807_eus-gaap--BasisOfAccounting_zMYqid3yrvK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2. <span id="xdx_824_z9SeX714Rr1k">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements, which include the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. All significant intercompany balances and transactions have been eliminated in consolidation. During the quarter and nine-month period ended September 30, 2025, there were no changes to the Company’s accounting policies. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the opinion of management, all adjustments, consisting only of normal recurring accruals considered necessary for a fair presentation, have been included in the accompanying unaudited condensed consolidated financial statements. Operating results for the nine months ended September 30, 2025 and 2024 are not necessarily indicative of the results that may be expected for any other interim period(s) or for any full year. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on February 27, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amounts reported in the Company’s condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Events and conditions arising subsequent to the most recent balance sheet date have been evaluated for their possible impact on the unaudited condensed consolidated financial statements and accompanying notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern Uncertainty</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since inception, the Company has incurred substantial operating losses, principally from expenses associated with the Company’s research and development programs, clinical trials conducted in connection with the Company’s drug candidates, and applications and submissions to the U.S. Food and Drug Administration (“FDA”). The Company has not generated significant revenue and has incurred significant net losses in each year since inception. For the nine months ended September 30, 2025, the Company had a net loss of $<span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250930_z0GmiwkeJmUe" title="Net loss">10.3</span> million and used $<span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250930_znPgQt8O9Rh7" title="Cash to fund operation">10.2</span> million to fund operations. As of September 30, 2025, the Company has incurred approximately $<span id="xdx_908_ecustom--CumulativeNetIncomeLoss_iI_pn6n6_c20250930_zytLWjQD7jM8" title="Cumulative net loss">419</span> million of cumulative net losses. As of September 30, 2025, the Company had $<span id="xdx_905_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20250930_zTcBh394Uu1f" title="Cash and cash equivalents, short-term investments, and interest receivable">5.3</span> million in cash and cash equivalents to fund its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U.S. and worldwide resulting from the recent tariff announcement by the U.S. federal government, the Russian invasion of Ukraine and the unrest in the Middle East. The Company continues to monitor its operating activities in light of these events, and it is possible that these events could result in a variety of risks to the business. The specific impact, if any, is not readily determinable as of the date of these unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has based its estimates on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company’s shares or debt and other sources. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of existing stockholders may be diluted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company’s control. These factors include the progress of research activities; the number and scope of research programs; the progress of preclinical and clinical development activities; the progress of the development efforts of parties with whom the Company has entered into research and development agreements; the costs associated with additional clinical trials of drug candidates; the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements; the ability to achieve milestones under licensing arrangements; the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and the costs and timing of regulatory approvals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A fundamental component of the ability to continue as a going concern is the Company’s ability to raise capital as required, as to which no assurances can be provided. To address the additional funding requirements of the Company, management has undertaken the following initiatives:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it has assessed its current expenditures and will reduce spending where necessary;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it will pursue additional capital funding in the public and private markets through equity sales and/or debt facilities;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it will pursue possible partnerships and collaborations; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it will pursue potential out licensing for its drug candidates.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s ability to continue as a going concern will depend on its ability to raise additional capital, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue. There are no assurances that these future funding and operating efforts will be successful. If management is unsuccessful in these efforts, the Company’s current capital is not expected to be sufficient to fund operations for the next twelve months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern. The report of our independent registered public accounting firm for the year ended December 31, 2024, includes an explanatory paragraph which expresses substantial doubt about our ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management’s plan includes private or public equity financings, collaborations, or other strategic transactions such as raising funds from outside investors via its ATM program and other potential funding sources. The Company may not be able to obtain funding on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control, and it may be unable to raise financing when needed, or on terms favorable to the Company. If the Company is unable to obtain sufficient capital to fund its operations it may be required to evaluate alternatives. The Company’s condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -10300000 -10200000 419000000 5300000 <p id="xdx_806_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zD4ycCfxlh1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3. <span id="xdx_823_zoUdqgcUi2y3">New Accounting Pronouncements</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s condensed consolidated financial position, results of operations, and cash flows, or do not apply to its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued Accounting Standards Update (“ASU”) No. 2023-09, “Improvements to Income Tax Disclosures”, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU No. 2023-09 is effective for the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Early adoption is permitted. The Company is currently evaluating the impact of the ASU on the income tax disclosures within the unaudited condensed consolidated financial statements; the Company expects changes to the Company’s income tax disclosure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU No. 2024-03, “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as “Cost of sales” and “Selling, general and administrative expenses”. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company’s disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zQar97wlpeTl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4. <span id="xdx_82C_zEAQ88fUzVx7">Net Loss per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per common share was computed by dividing net loss for the year by the weighted average number of shares of common stock outstanding, both basic and diluted, during each period. The impact of common stock equivalents has been excluded from the computation of diluted weighted average common shares outstanding in periods where there is a net loss, as their effect is anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of shares of common stock issuable upon exercise of warrants, stock option grants and equity awards was <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250930_zzq8ZlrA3sSa" title="Anti-dilutive securities">990,233</span> and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zu0xOsm0jnDj" title="Anti-dilutive securities">447,499</span> shares for the nine months ended September 30, 2025 and 2024, respectively. For the nine-month periods ended September 30, 2025 and 2024, diluted loss per common share was the same as basic loss per common share as the other warrants, and equity awards that were convertible into shares of the Company’s common stock were excluded from the calculation of diluted loss per common share as their effect would have been anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company declared a <span id="xdx_900_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250807__20250807_ztotABs9zQH9" title="Stock dividend percentage">15</span>% stock dividend that was distributed on August 21, 2025 to stockholders of record as of August 7, 2025. In accordance with Accounting Standards Codification (“ASC”) 260, basic and diluted earnings per share amounts and weighted-average shares outstanding have been restated for all periods presented to reflect the effect of this stock dividend. The Company did not pay any dividends during the first nine months of 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 990233 447499 0.15 <p id="xdx_803_eus-gaap--SegmentReportingDisclosureTextBlock_zL9mgZSRqWHk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5. <span id="xdx_82C_zrvNg5hLMjvk">Segment Performance Measures and Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in <span id="xdx_907_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20250101__20250930_zgVq2DIheIah" title="Number of operating segment">one</span> segment for the research and development of product candidates. The Company’s chief operating decision maker (“CODM”) has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company based on condensed consolidated financial information. Consequently, the Company views the entire organization as <span id="xdx_907_eus-gaap--NumberOfReportableSegments_pid_dc_uSegment_c20250101__20250930_zbCBzn4Jo3Ph" title="Number of reportable segment">one</span> reportable segment and the strategic purpose of all operating activities (including general and administrative expenses) is to support that one segment. As a pre-revenue research and development company, the CODM evaluates company-wide performance and allocates resources based on non-financial research and development milestones achieved, and to a lesser extent, financial measures of performance such as clinical development (research and development expenses) and general and administrative expenses incurred. The CODM does not generally evaluate the Company’s performance using asset or historical cash flow information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zPy9KZHIER7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zIILSfo8qSW7" style="display: none">Schedule of Significant Expense Categories and Consolidated Net Loss</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zEsuRamHFfJ4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240101__20240930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zp252wxGkhKl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(In thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change Increase</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Decrease)</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating Expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Clinical Research</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OvationTwoAndMRDTrialsMember_zwDHczL5XZpe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 36%; text-align: left">OVATION 2 and MRD Trials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">212</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,139</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OvationTwoAndMRDTrialsMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zNojSCihkBhe" style="width: 12%; text-align: right">(927</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--OvationTwoAndMRDTrialsMember_zF2WNXJSRit5" style="width: 12%; text-align: right">(81.4</td><td style="width: 1%; text-align: left">)%</td></tr> <tr id="xdx_40F_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OvationThreeMember_zaKtQmDoRpw8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">OVATION 3 Trial</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OvationThreeMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zkQVPBzCtBpj" style="text-align: right">695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--OvationThreeMember_zOz2AEgVwrg7" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></td><td style="text-align: left">%</td></tr> <tr id="xdx_403_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember_zBdWyliy5606" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">PlaCCine Vaccine Phase 1 Trial</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,412</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_ziGiStk3fvj4" style="text-align: right">(1,370</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember_zwKFzOLYFnhh" style="text-align: right">(97.0</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40F_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OtherClinicalAndRegulatoryMember_zQpOA3ud3O2d" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Other Clinical and Regulatory</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,387</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,900</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OtherClinicalAndRegulatoryMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zcwyv4tmK6Pk" style="border-bottom: Black 1pt solid; text-align: right">(513</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--OtherClinicalAndRegulatoryMember_zJnVspdtIri3" style="border-bottom: Black 1pt solid; text-align: right">(27.0</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_401_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember_zB3DzpqpB659" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 30pt">Subtotal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,336</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,451</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z6IWveAx7X8b" style="text-align: right">(2,115</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zUKriQwaYVn9" style="text-align: right">(47.5</td><td style="text-align: left">)%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Non-Clinical R&amp;D and CMC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__us-gaap--SubsegmentsAxis__custom--OvationMember_zgvK4sI6SGif" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">OVATION Program</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,209</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">851</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--OvationMember_zZAYFx5tq6o5" style="text-align: right">1,358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--OvationMember_znTcpCdwEpDc" style="text-align: right">159.6</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__us-gaap--SubsegmentsAxis__custom--PlaCCineVaccineMember_z7TRzTD3CQdg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">PlaCCine Vaccine Program</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,554</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember_zhYYH6YkwR4j" style="text-align: right">(2,554</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember_zv3v3iFItke6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0721">-</span></td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__us-gaap--SubsegmentsAxis__custom--ManufacturingCMCMember_z6Svni6zQqgc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Manufacturing (CMC)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">746</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,551</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--ManufacturingCMCMember_zO5ivsW6TiH" style="border-bottom: Black 1pt solid; text-align: right">(805</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--ManufacturingCMCMember_zEovifAQGI8j" style="border-bottom: Black 1pt solid; text-align: right">(51.9</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_409_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember_z4XsBW1FGRo9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 30pt; padding-bottom: 1pt">Subtotal</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,955</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,956</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zyy2pfxmoglh" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal">(2,001</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zMzqZkUKl65h" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal, percentage">(40.4</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_z6SBfmftGE4k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,407</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zgRSwkPxZ831" style="text-align: right" title="Change Increase (Decrease), Research and development expenses">(4,116</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--IncreaseDecreaseInResearchAndDevelopmentExpensesPercentage_dp_uPure_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zDvysC55pvW6" title="Change Increase (Decrease), Research and development expenses, percentage">(43.8</span></td><td style="text-align: left">)%</td></tr> <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_zQZLLKZkegmg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,098</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,580</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--IncreaseDecreaseInGeneralAndAdministrativeExpenes_pn3n3_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zxtCalgdnMii" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), General and administrative expenses">(482</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--IncreaseDecreaseInGeneralAndAdministrativeExpensesPercentage_dp_uPure_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_ztyu29xmRyPh" title="Change Increase (Decrease), General and administrative expenses, percentage">(8.6</span></td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_40B_eus-gaap--OperatingExpenses_pn3n3_zhVyN9Bm9Uea" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,389</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,987</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--IncreaseDecreaseInOperatingExpenses_pn3n3_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_za7NrWlhe47d" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Operating expenses">(4,598</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--IncreaseDecreaseInOperatingExpensesPercentage_dp_uPure_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z3LR7bqMFhCl" title="Change Increase (Decrease), Operating expenses, percentage">(30.7</span></td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_400_eus-gaap--OperatingIncomeLoss_pn3n3_zl34t615gwZk" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(10,389</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(14,987</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--IncreaseDecreaseInLossFromOperations_pn3n3_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zmDcE57P3Kpj" style="border-bottom: Black 2.5pt double; text-align: right" title="Change Increase (Decrease), Loss from operations">(4,598</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--IncreaseDecreaseInLossFromOperationsPercentage_dp_uPure_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zKZDukQw6Qz9" title="Change Increase (Decrease), Loss from operations, percentage">(30.7</span></td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr> </table> <p id="xdx_8A1_zKkY1f2KfEhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1 1 <p id="xdx_89A_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zPy9KZHIER7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zIILSfo8qSW7" style="display: none">Schedule of Significant Expense Categories and Consolidated Net Loss</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zEsuRamHFfJ4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240101__20240930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zp252wxGkhKl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(In thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change Increase</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Decrease)</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating Expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Clinical Research</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OvationTwoAndMRDTrialsMember_zwDHczL5XZpe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 36%; text-align: left">OVATION 2 and MRD Trials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">212</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,139</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OvationTwoAndMRDTrialsMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zNojSCihkBhe" style="width: 12%; text-align: right">(927</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--OvationTwoAndMRDTrialsMember_zF2WNXJSRit5" style="width: 12%; text-align: right">(81.4</td><td style="width: 1%; text-align: left">)%</td></tr> <tr id="xdx_40F_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OvationThreeMember_zaKtQmDoRpw8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">OVATION 3 Trial</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OvationThreeMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zkQVPBzCtBpj" style="text-align: right">695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--OvationThreeMember_zOz2AEgVwrg7" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></td><td style="text-align: left">%</td></tr> <tr id="xdx_403_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember_zBdWyliy5606" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">PlaCCine Vaccine Phase 1 Trial</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,412</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_ziGiStk3fvj4" style="text-align: right">(1,370</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember_zwKFzOLYFnhh" style="text-align: right">(97.0</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40F_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OtherClinicalAndRegulatoryMember_zQpOA3ud3O2d" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Other Clinical and Regulatory</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,387</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,900</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__us-gaap--SubsegmentsAxis__custom--OtherClinicalAndRegulatoryMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zcwyv4tmK6Pk" style="border-bottom: Black 1pt solid; text-align: right">(513</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--OtherClinicalAndRegulatoryMember_zJnVspdtIri3" style="border-bottom: Black 1pt solid; text-align: right">(27.0</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_401_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember_zB3DzpqpB659" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 30pt">Subtotal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,336</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,451</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z6IWveAx7X8b" style="text-align: right">(2,115</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalResearchMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zUKriQwaYVn9" style="text-align: right">(47.5</td><td style="text-align: left">)%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Non-Clinical R&amp;D and CMC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__us-gaap--SubsegmentsAxis__custom--OvationMember_zgvK4sI6SGif" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">OVATION Program</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,209</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">851</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--OvationMember_zZAYFx5tq6o5" style="text-align: right">1,358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--OvationMember_znTcpCdwEpDc" style="text-align: right">159.6</td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__us-gaap--SubsegmentsAxis__custom--PlaCCineVaccineMember_z7TRzTD3CQdg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">PlaCCine Vaccine Program</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,554</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember_zhYYH6YkwR4j" style="text-align: right">(2,554</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--PlaccineVaccineMember_zv3v3iFItke6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0721">-</span></td><td style="text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__us-gaap--SubsegmentsAxis__custom--ManufacturingCMCMember_z6Svni6zQqgc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Manufacturing (CMC)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">746</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,551</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--ManufacturingCMCMember_zO5ivsW6TiH" style="border-bottom: Black 1pt solid; text-align: right">(805</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--SubsegmentsAxis__custom--ManufacturingCMCMember_zEovifAQGI8j" style="border-bottom: Black 1pt solid; text-align: right">(51.9</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_409_eus-gaap--OperatingCostsAndExpenses_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember_z4XsBW1FGRo9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 30pt; padding-bottom: 1pt">Subtotal</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,955</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,956</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zyy2pfxmoglh" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal">(2,001</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--IncreaseDecreaseInOperatingCostsAndExpensesPercentage_pid_dp_uPure_c20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NonClinicalRAndDAndCMCMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zMzqZkUKl65h" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Subtotal, percentage">(40.4</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_z6SBfmftGE4k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,407</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--IncreaseDecreaseInOperatingCostAndExpenses_pn3n3_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zgRSwkPxZ831" style="text-align: right" title="Change Increase (Decrease), Research and development expenses">(4,116</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--IncreaseDecreaseInResearchAndDevelopmentExpensesPercentage_dp_uPure_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zDvysC55pvW6" title="Change Increase (Decrease), Research and development expenses, percentage">(43.8</span></td><td style="text-align: left">)%</td></tr> <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_zQZLLKZkegmg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,098</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,580</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--IncreaseDecreaseInGeneralAndAdministrativeExpenes_pn3n3_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zxtCalgdnMii" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), General and administrative expenses">(482</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--IncreaseDecreaseInGeneralAndAdministrativeExpensesPercentage_dp_uPure_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_ztyu29xmRyPh" title="Change Increase (Decrease), General and administrative expenses, percentage">(8.6</span></td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_40B_eus-gaap--OperatingExpenses_pn3n3_zhVyN9Bm9Uea" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,389</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,987</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--IncreaseDecreaseInOperatingExpenses_pn3n3_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_za7NrWlhe47d" style="border-bottom: Black 1pt solid; text-align: right" title="Change Increase (Decrease), Operating expenses">(4,598</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--IncreaseDecreaseInOperatingExpensesPercentage_dp_uPure_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z3LR7bqMFhCl" title="Change Increase (Decrease), Operating expenses, percentage">(30.7</span></td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_400_eus-gaap--OperatingIncomeLoss_pn3n3_zl34t615gwZk" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(10,389</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(14,987</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--IncreaseDecreaseInLossFromOperations_pn3n3_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zmDcE57P3Kpj" style="border-bottom: Black 2.5pt double; text-align: right" title="Change Increase (Decrease), Loss from operations">(4,598</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--IncreaseDecreaseInLossFromOperationsPercentage_dp_uPure_c20250101__20250930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zKZDukQw6Qz9" title="Change Increase (Decrease), Loss from operations, percentage">(30.7</span></td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr> </table> 212000 1139000 -927000 -0.814 695000 695000 42000 1412000 -1370000 -0.970 1387000 1900000 -513000 -0.270 2336000 4451000 -2115000 -0.475 2209000 851000 1358000 1.596 2554000 -2554000 746000 1551000 -805000 -0.519 2955000 4956000 -2001000 -0.404 5291000 9407000 -4116000 -0.438 5098000 5580000 -482000 -0.086 10389000 14987000 -4598000 -0.307 -10389000 -14987000 -4598000 -0.307 <p id="xdx_803_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zahhDLn6KSsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6. <span id="xdx_824_zBBM9we4zKd5">Other Accrued Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zvfvSNlItll5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other accrued liabilities at September 30, 2025 and December 31, 2024 include the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zymVgwkSOtaj" style="display: none">Schedule of Other Accrued Liabilities</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20250930_zpUiDGN8Prab" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20241231_zGDJZuHnSdQ7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--ContractualObligation_iI_maCz80K_z2iPgulvJwAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Amounts due to contract research organizations and <br/>other contractual agreements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">910,501</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,048,036</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maCz80K_zsTKxfYgske3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued payroll and related benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,687,690</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,945,111</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maCz80K_zvTSYvorzLm8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accrued professional fees and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">78,760</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40,600</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtCz80K_zyLhasweOn9h" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,676,951</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,033,747</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zoDaQ7H3TRA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zvfvSNlItll5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other accrued liabilities at September 30, 2025 and December 31, 2024 include the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zymVgwkSOtaj" style="display: none">Schedule of Other Accrued Liabilities</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20250930_zpUiDGN8Prab" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20241231_zGDJZuHnSdQ7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--ContractualObligation_iI_maCz80K_z2iPgulvJwAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Amounts due to contract research organizations and <br/>other contractual agreements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">910,501</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,048,036</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_maCz80K_zsTKxfYgske3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued payroll and related benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,687,690</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,945,111</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_maCz80K_zvTSYvorzLm8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accrued professional fees and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">78,760</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40,600</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtCz80K_zyLhasweOn9h" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,676,951</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,033,747</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 910501 1048036 1687690 1945111 78760 40600 2676951 3033747 <p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwv0z5E15eY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7. <span id="xdx_821_zb7gG0ZlRzq6">Stockholders’ Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 15, 2024, the Company filed with the U.S. Securities and Exchange Commission (“SEC”) a shelf registration statement on Form S-3 (the “2024 Registration Statement”) for the offer and sale of up to $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn6n6_c20240515__20240515_z5v9F7mHb6H6" title="Stock issued during period, value, new issues">75</span> million of its securities. The 2024 Registration Statement was declared effective on May 22, 2024. The 2024 Registration Statement is intended to provide the Company with flexibility to raise capital in the future for general corporate purposes. As noted in the prospectus supplement that the Company filed on July 22, 2025, the aggregate market value of outstanding Common Stock held by non-affiliates was approximately $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250722__20250722_z8vhJZa1qwC4" title="Aggregrate value">79,075,969</span>, based on <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250722__20250722_zDYAn5d8WDcl" title="Issuance of common shares">2,121,895</span> shares of Common Stock outstanding as of July 22, 2025, of which <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250602__20250602_zCJfhjTFQry8" title="Issuance of common shares">2,100,291</span> shares were held by non-affiliates, and a price of $<span id="xdx_900_eus-gaap--SharePrice_iI_c20250602_zUKHyWHnZ3g6" title="Share price">37.65</span> per share, which was the last reported sale price of Common Stock on The Nasdaq Stock Market LLC (“Nasdaq”) on June 2, 2025. As a result, the Company’s public float increased above $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240515__20240515_zvoDwrcFaSzh" title="Stock issued during period, value, new issues">75.0</span> million, and the Company is no longer subject to the limitations contained in General Instruction I.B.6 of Form S-3.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse Stock Split</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 25, 2025, the Company effected a <span id="xdx_902_eus-gaap--StockholdersEquityReverseStockSplit_c20250725__20250725_z3v4PMeNJwyf" title="Reverse stock split">15-for-1 reverse stock split</span> of its common stock which was made effective for trading purposes as of 12:01 a.m. ET on July 25, 2025. As of that date, each <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20250725_zDgeYZujKILa" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20250725_zWJTajU0CGhk" title="Common stock, shares outstanding">15</span></span> shares of issued and outstanding common stock and equivalents were consolidated into one share of common stock. All shares have been restated to reflect the effects of the <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20250725__20250725_zuIYEEAJpURb" title="Reverse stock split">15-for-1 reverse stock split</span>. In addition, at the market open on July 25, 2025, the Company’s common stock started trading under a new CUSIP number 15117N701 although the Company’s ticker symbol, IMNN, remained unchanged.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reverse stock split was previously approved by the Company’s stockholders at the 2025 Annual Meeting held on July 11, 2025, and the Company subsequently filed a Certificate of Amendment to its Certificate of Incorporation to effect the stock consolidation. The primary reasons for the reverse stock split and the amendment are:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To provide the Company with the ability to support its future anticipated growth and would provide greater flexibility to consider and respond to future business opportunities and needs as they arise, including equity financings and stock-based acquisitions of new technology and product development candidates. The availability of additional shares of Common Stock would permit the Company to undertake certain of the foregoing actions without delay and expense associated with holding a Special Meeting of Stockholders to obtain stockholder approval each time such an opportunity arises that would require the issuance of shares of Common Stock; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To continue listing on The NASDAQ Capital Market, which requires that the Company comply with the applicable listing requirements under NASDAQ Marketplace Rules, which requirements include, among others, a minimum bid price of at least $<span id="xdx_906_eus-gaap--SharePrice_iI_c20250725_zPOoouz9WsHe" title="Share price">1.00</span> per share.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately prior to the reverse stock split, the Company had <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20250725__20250725_zoTItVsH2OGl" title="Reverse stock split shares">31,828,447</span> shares of common stock outstanding which consolidated into <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20250725__20250725__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWQI9uvl05Va" title="Reverse stock split shares">2,121,942</span> shares of the Company’s common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares were rounded up to the nearest whole share. The reverse stock split did not impact the total authorized number of shares of common or preferred stock or the par value thereof. The number of outstanding options, stock awards and warrants were adjusted accordingly, with outstanding options and stock awards being reduced from approximately <span id="xdx_90A_ecustom--OptionsOutstanding_iI_pn5n6_c20250725__srt--RangeAxis__srt--MaximumMember_zISJqiSpVYxd" title="Options outstanding">1.9</span> million to approximately <span id="xdx_901_ecustom--OptionsOutstanding_iI_pn5n6_c20250725__srt--RangeAxis__srt--MinimumMember_ztXTLBnCAUZb" title="Options outstanding">0.1</span> million and outstanding warrants being reduced from approximately <span id="xdx_906_ecustom--StockAwardsReduced_iI_pn5n6_c20250725__srt--RangeAxis__srt--MaximumMember_zD4ICvuWu0hh" title="Stock awards reduced">12.7</span> million to approximately <span id="xdx_901_ecustom--StockAwardsReduced_iI_pn5n6_c20250725__srt--RangeAxis__srt--MinimumMember_zmzYYqipkzj2" title="Stock awards reduced">0.8</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Increase to Authorized Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company held on July 11, 2025, upon the recommendation of the Company’s board of directors, the Company’s stockholders voted on and approved an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20250711__srt--RangeAxis__srt--MinimumMember_zazGgpRMmGo9" title="Number of authorized shares of common stock">112,500,000</span> shares to <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20250711__srt--RangeAxis__srt--MaximumMember_zcpRzEvgkqFk" title="Number of authorized shares of common stock">350,000,000</span> shares, and to make a corresponding change to the number of authorized shares of capital stock. Such amendment became effective on July 11, 2025 upon filing with the Secretary of State of the State of Delaware.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Dividend</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 28, 2025, the Company announced that the Company’s Board of Directors approved a <span id="xdx_907_ecustom--StockDividendRatePercentage_iI_pid_dp_uPure_c20250728_zklOFwuYYEn6" title="Stock dividend percentage">15</span>% stock dividend, <span id="xdx_903_ecustom--DividendsCommonStocktPerShare_iI_c20250728_zkTxYAgY4f6e" title="Dividend per share">0.15</span> shares of common stock (the “Stock Dividend”) per share of the Company’s issued and outstanding shares of common stock and per each common stock equivalent with dividend rights.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors fixed August 7, 2025 as the record date (the “Record Date”) for the Stock Dividend, and the Stock Dividend was issued on August 21, 2025 to stockholders of record as of the Record Date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">The number of outstanding warrants were adjusted accordingly, with outstanding warrants increasing from approximately <span id="xdx_90E_ecustom--StockAwardsReduced_iI_pn5n6_c20250728__srt--RangeAxis__srt--MaximumMember_zw5JoauLSkg6" title="Stock awards reduced">0.8</span> million to approximately <span id="xdx_90F_ecustom--StockAwardsReduced_iI_pn5n6_c20250728__srt--RangeAxis__srt--MinimumMember_zWiwnA8LSbpe" title="Stock awards reduced">1.0</span> million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">At the Market Offering Agreement</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 15, 2024, the Company amended the At the Market Offering Agreement, dated as of May 25, 2022 (the “ATM Agreement”) with H.C. Wainwright &amp; Co., LLC (“Wainwright”) as sales agent. Pursuant to the terms of the amended ATM Agreement, the Company may offer and sell, from time to time, through Wainwright, shares of the Company’s common stock having an aggregate offering price of up to $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240515__20240515__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zWacMbZH4Mka" title="Stock issued during period, value, new issues">5,500,000</span>. The Company intends to use the net proceeds from any offering under the amended ATM Agreement for general corporate purposes, including research and development activities, capital expenditures and working capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 30, 2024, the Company notified Wainwright that it was suspending its use of and terminating the “at the market offering” sales agreement prospectus (the “ATM Prospectus”), related to the potential issuance from time to time of the Company’s common stock pursuant to the ATM Agreement, by and between the Company and Wainwright. Notwithstanding the termination of the ATM Prospectus, the ATM Agreement remains in full force and effect.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 3, 2024, the Company filed a new prospectus supplement to the 2024 Registration Statement with the SEC for an aggregate offering price of up to $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240903__20240903_zYbx7eVvrYNi" title="Issuance of common stock">5,500,000</span> related to the potential issuance from time to time of the Company’s common stock pursuant to the ATM Agreement with Wainwright as sales agent.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 22, 2025, the Company filed a prospectus supplement (the “Prospectus Supplement”) to register an additional $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250722__20250722__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zFXVtir8Hsha" title="Stock issued during period, value, new issues">4,500,000</span> of shares of the Company’s common stock, par value $<span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20250722__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_z5aazWqUVYJa" title="Share price">0.01</span> per share issuable pursuant to the At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the “Sales Agreement”), by and between the Company and H.C. Wainwright &amp; Co., LLC, as sales agent or principal (the “Sales Agent”). The Company previously registered the offer and sale of up to $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250722__20250722__us-gaap--IncomeStatementLocationAxis__custom--SalesAgreementMember_zpwLbucC4qPf" title="Issuance of common stock">5,500,000</span> of shares of Common Stock through the Sales Agent under the Sales Agreement. Prior to the date hereof, the Company has sold an aggregate of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250722__20250722_znI82Xd5cGUj" title="Issuance of common stock">1,815,267</span> shares of Common Stock through the Sales Agent under the Sales Agreement. Accordingly, the Prospectus Supplement covers an aggregate of $<span id="xdx_90E_ecustom--AggregateShares_c20250722__20250722_zYvY2JTygDJ8" title="Prospectus supplement covers aggregate shares">8,184,733</span> of Shares, consisting of $<span id="xdx_90D_ecustom--RemainingShareAmount_c20250722__20250722_z6ECtdjrJZvf" title="Remaining amount">3,684,733</span> remaining of the amount originally registered and the additional $<span id="xdx_904_ecustom--AdditionalProspectusSupplementAmount_c20250722__20250722_zCgPmyYnyZo8" title="Additional prospectus supplement amount">4,500,000</span> increase under the Prospectus Supplement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company sold <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zqggI04uYBw7" title="Number of shares sold">5,932</span> shares of common stock under the ATM Agreement for net proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zEv4Cvenqsue" title="Proceeds from sale of stock">99,506</span> during 2024. During 2025, the Company sold <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zK2JoUJRvaif" title="Number of shares sold">551,265</span> shares of common stock under the ATM Agreement for net proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zBnCeHVWkOh7" title="Proceeds from sale of stock">3,638,767</span> through September 30, 2025. The Company sold <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251001__20251113__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlQV0vuighFj" title="Number of shares sold">174,081</span> shares of common stock under the ATM Agreement for net proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20251001__20251113__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z94S6xIKB0kl" title="Proceeds from sale of stock">816,030</span> subsequent to September 30, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">July 2024 Offering</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 30, 2024, the Company entered into the July 2024 Purchase Agreement with the Purchasers, pursuant to which the Company issued, in a registered direct offering, an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240730__20240730__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFourOfferingMember_zp5w431dJ6p1" title="Stock issued, shares">333,334</span> shares of the Company’s common stock at an offering price of $<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20240730__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFourOfferingMember_z8VDwiirNTmg" title="Share price">30.00</span> per share for gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240730__20240730__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFourOfferingMember_zOcNjhIHAPa3" title="Proceeds from issuance of common stock">10.0</span> million before the deduction of placement agent fees and offering expenses. In a concurrent private placement and also pursuant to the July 2024 Purchase Agreement, the Company issued to the Purchasers the Warrants to purchase an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240730__20240730__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFourOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsLb0pHFk5S6" title="Stock issued, shares">333,334</span> shares of its common stock at an exercise price of $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20240730__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFourOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfeTfrCyZdIc" title="Share price">30.00</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Warrants became exercisable immediately after issuance for a term of five and one-half years following the date of issuance. The closing of the July 2024 Offering occurred on August 1, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 12, 2025, the Company entered into an exchange agreement (the “Agreement”) with the holders (the “Warrant Holders”) of certain warrants of the Company issued on August 1, 2024, which are exercisable for an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250512__20250512__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFourOfferingMember_zS2NFc5pExr3" title="Issuance of shares">333,334</span> shares of the Company’s common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250512__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFourOfferingMember_zxPPnYmIkbs5" title="Common stock par value">0.01</span> per share. Pursuant to the terms of the Agreement, the Company will issue to the Warrant Holders an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250512__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFourOfferingMember_zXzMqBZMoqOg" title="Warrants outstanding">194,734</span> shares of Common Stock (the “Warrant Exchange Shares”), on a one-for-one basis, in exchange for shares issuable under the Warrants (the “Warrant Exchange”), in reliance on an exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to the Agreement, the Warrant Holders also agreed to waive the Company’s compliance with the provisions of Section 4.12(b) of the Securities Purchase Agreement, dated July 30, 2024, with respect to any Company Variable Rate Transaction (as defined in the Purchase Agreement) for a period of forty-five (45) days from the date of the Agreement and agreed to a lock up period on the Warrant Exchange Shares ending on the opening of trading on May 14, 2025. The Warrant Exchange closed on May 13, 2025. The number of Warrant Exchange Shares that will be issued pursuant to the Agreement will represent <span id="xdx_903_ecustom--CommonStockOutstandingPercentage_iI_pid_dp_uPure_c20250512__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFourOfferingMember_zkn9bqMf7mdl" title="Common stock outstanding percentage">19.98</span>% of the shares of Common Stock outstanding as of the date of the Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">May 2025 Offering</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 23, 2025, the Company entered into a Securities Purchase Agreement with certain institutional and accredited investors, for the issuance and sale in a private placement of (i) <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250523__20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember_zI7AKC6AqARg" title="Stock issued, shares">185,186</span> shares of the Company’s common stock, (ii) <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250523__20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedMember_zn4NxiUahHq6" title="Stock issued, shares">296,297</span> of pre-funded warrants at an exercise price of $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedMember_zQhDaGtHZ5ce" title="Share price">0.0001</span> per share and (iii) <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250523__20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zd0JcfMoHSLl" title="Stock issued, shares">962,964</span> warrants at an exercise price of $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZeAJRJwBbH6" title="Share price">6.75</span> per share for gross proceeds of approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250523__20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember_z3ChNcIK5QN4" title="Proceeds from issuance of common stock">3.3</span> million before the deduction of placement agent fees and offering expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Prefunded Warrants became exercisable immediately after issuance for a term of two and one-half years following the date of issuance. The Warrants will be exercisable upon receipt of such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity) from the stockholders of the Company with respect to issuance of all of the Warrants and the shares of Common Stock upon the exercise thereof (“Stockholder Approval,” and such date, the “Stockholder Approval Date”) and have a term of three years. The prefunded warrants were exercised in full on June 16, 2025 and June 18, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company issued to H.C. Wainwright &amp; Co., LLC warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250523__20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentsWarrantMember_zkLQTqxUQIN7" title="Stock issued, shares">24,075</span> shares of common stock at an exercise price equal to $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20250523__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayTwoThousandTwentyFiveOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentsWarrantMember_zbMYSg8iS7oi" title="Share price">8.44</span> per share. The Placement Agent Warrants have substantially the same terms as the Warrants. The closing of the May 2025 Offering occurred on May 28, 2025. On July 11, 2025, the Company’s stockholders approved the issuance of the Warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 75000000 79075969 2121895 2100291 37.65 75000000.0 15-for-1 reverse stock split 15 15 15-for-1 reverse stock split 1.00 31828447 2121942 1900000 100000 12700000 800000 112500000 350000000 0.15 0.15 800000 1000000.0 5500000 5500000 4500000 0.01 5500000 1815267 8184733 3684733 4500000 5932 99506 551265 3638767 174081 816030 333334 30.00 10000000.0 333334 30.00 333334 0.01 194734 0.1998 185186 296297 0.0001 962964 6.75 3300000 24075 8.44 <p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zYLSffq5dHf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8. <span id="xdx_82C_zaBSGTMLD8F3">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has long-term compensation plans that permit the granting of equity-based awards in the form of stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, and performance awards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2018, stockholders approved the Imunon, Inc. 2018 Stock Incentive Plan (the “2018 Plan”). The 2018 Plan, as amended, permits the granting of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_z7zib09LL5Y4" title="Number of shares authorized">131,334</span> shares of Imunon common stock as equity awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, other stock awards, performance awards, or in any combination of the foregoing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2025, there were a total of <span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20250930__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_z2U4iLSJiLMe" title="Common stock, reserved for future issuance">264,667</span> shares of Imunon common stock reserved for issuance under the 2018 Plan, which were comprised of <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20250930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--GrantedUnderTwoThousandEighteenPlanAndTwoThousandSevenPlanMember_zX8Z6h978nv4" title="Common stock, reserved for future issuance">24,986</span> shares of Imunon common stock subject to equity awards previously granted under the 2018 Plan and <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250930__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_zrV5U6KV9tBa" title="Shares available for issuance">235,509</span> shares of Imunon common stock available for future issuance under the 2018 Plan. At the 2025 Annual Stockholders Meeting of the Company held on July 11, 2025, stockholders approved an amendment to the 2018 Plan, as previously amended, whereby the Company increased the number of shares of common stock available by <span id="xdx_908_eus-gaap--CommonStockSharesHeldInEmployeeTrustShares_iI_c20250930__us-gaap--PlanNameAxis__custom--TwoThousandAndEighteenStockIncentivePlanMember_zoFiChytIYil" title="Number of shares common stock">133,333</span> to a total of <span id="xdx_90E_eus-gaap--CommonStockSharesHeldInEmployeeTrustShares_iI_c20250930__us-gaap--AwardTypeAxis__custom--EquityStockAwardsMember__srt--StatementScenarioAxis__custom--TwoThousandEighteenPlanMember_zYywpgPD5hq1" title="Number of shares common stock">264,667</span> under the 2018 Plan, as amended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total compensation cost related to stock options and restricted stock awards was approximately $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250930__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionAndRestrictedStockAwardsMember_zVWZrm9OIpdf" title="Share based compensation">0.1</span> million and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20240930__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionAndRestrictedStockAwardsMember_zfbi20jRK8fg" title="Share based compensation">0.4</span> million of expense for the nine months ended September 30, 2025 and 2024, respectively. Of these amounts, approximately $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionAndRestrictedStockAwardsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zybWLD9YXIt" title="Research and development expenses">29,000</span> for the nine months ended September 30, 2025 and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20240930__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionAndRestrictedStockAwardsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zAO3enDyC6Gd" title="Research and development expenses">0.2</span> million expense for the same period ended September 30, 2024 were charged to research and development expenses and $<span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_pn5n6_c20250101__20250930__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionAndRestrictedStockAwardsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zDEJXKTZA9ij" title="General and administrative expenses">0.1</span> million of expense for the nine months ended September 30, 2025 and $<span id="xdx_90E_eus-gaap--GeneralAndAdministrativeExpense_pn5n6_c20240101__20240930__us-gaap--AwardTypeAxis__custom--EmployeeStockOptionAndRestrictedStockAwardsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zhqYbLOvpHNj" title="General and administrative expenses">0.2</span> million of expense for the nine months ended September 30, 2024 were charged to general and administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_ecustom--SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock_znP3H8jszU0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of stock option awards and restricted stock grants, inclusive of awards granted under the 2018 Stock Plan and Inducement Option Grants for the nine months ended September 30, 2025 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zm9XqMwh7guf" style="display: none">Schedule of Stock Options Awards and Restricted Stock Grants</span></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restricted Stock Awards</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-vested</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in years)</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Equity awards outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEjNk7MRoiYk" style="width: 8%; text-align: right" title="Options outstanding, beginning balance">107,865</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYSvnFk0dPB3" style="width: 8%; text-align: right" title="Weighted average exercise price, beginning balance">28.97</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDigw3GaAqd4" style="width: 8%; text-align: right" title="Non-vested stock awards, beginning balance">2,647</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhfqZXKQw2Cl" style="width: 8%; text-align: right" title="Weighted average grant date fair value, beginning balance">14.85</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Equity awards granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z13XqfESFrnd" style="text-align: right" title="Options outstanding, granted">35,693</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zehXpYNUcGMh" style="text-align: right" title="Weighted average exercise price, granted">11.44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zATV9qpMJ077" style="text-align: right" title="Non-vested stock awards, granted"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFEkLAxARoS3" style="text-align: right" title="Weighted average grant date fair value, granted"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Equity awards issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssued_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbk6ClH3a3uj" style="text-align: right" title="Options outstanding, issued"><span style="-sec-ix-hidden: xdx2ixbrl0935">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionIssuedWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1hAKgvbZTQb" style="text-align: right" title="Weighted average exercise price, issued"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssued_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1S0DY3g6Mxc" style="text-align: right" title="Non-vested stock awards, issued">2,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYu7HX23Ltq9" style="text-align: right" title="Weighted average grant date fair value, issued">14.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Equity awards terminated or forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEKSWJtTaGP8" style="border-bottom: Black 1pt solid; text-align: right" title="Equity awards terminated or forfeited">(118,572</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zraznAyN1oii" style="padding-bottom: 1pt; text-align: right" title="Equity awards terminated or forfeited">25.56</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOeZtpYKtcGd" style="border-bottom: Black 1pt solid; text-align: right" title="Non-vested stock awards, Terminated"><span style="-sec-ix-hidden: xdx2ixbrl0947">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziOFVr5taCPf" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, Terminated or forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0949">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Equity awards outstanding at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgmpWgYmMied" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending balance">24,986</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm0l9ED4cA6b" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, ending balance">20.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zObtNvP9wFJb" style="border-bottom: Black 2.5pt double; text-align: right" title="Non-vested stock awards, ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLPm7IWvjCJ2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgtpUGQwTPNa" title="Weighted average contractual terms">8.8</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Equity awards exercisable at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8untn9LNRa" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, exercisable">17,292</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zStYACzEd35d" style="text-align: right" title="Weighted average exercise price, exercisable">24.85</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znHd6sgVrWl1" title="Weighted average contractual terms, exercisable">8.4</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Aggregate intrinsic value of equity awards exercisable at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTUXoHB74fzg" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, aggregate intrinsic value, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0967">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zChWJniOhSZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2025, there was $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20250930_zjdjqaH37rmf" title="Unrecognized compensation cost">58,000</span> of total unrecognized compensation cost related to non-vested stock-based compensation arrangements. That cost is expected to be recognized over a period of three <span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20250930__srt--RangeAxis__srt--MinimumMember_zDwMunHABgBi" style="display: none" title="Cost recognized period">3</span> to <span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc_c20250101__20250930__srt--RangeAxis__srt--MaximumMember_zztSl1pVBi88" title="Cost recognized period">four years</span>. The weighted average grant date fair value of the stock options granted was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z42ALlE8EBSa" title="Weighted average grant date fair value per share">11.44</span> during the nine months ended September 30, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zPNW65GRsDqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from the Company’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zpVXNLFJJ91b" style="display: none">Schedule of Assumptions Used to Determine Fair Value of Options Granted</span></span></span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Risk-free interest rate</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20250930_zLumz3kqlcm5" title="Risk-free interest rate, minimum">4.22</span> to <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20250930_zPRtt4JLCSF" title="Risk-free interest rate, maximum">4.55</span></td><td>%</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20240930_zm1Ype340Jek" title="Risk-free interest rate, minimum">3.72</span> to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20240930_z65lDjcgugo8" title="Risk-free interest rate, maximum">4.31</span></td><td>%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected volatility</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20250930_zvMs1K2yQJTk" title="Expected volatility, minimum">110.74</span> to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20250930_zHL982cXr88b" title="Expected volatility, maximum">123.22</span></td><td>%</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20240930_zSrFGvebFBib" title="Expected volatility, minimum">101.74</span> to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20240930_zZbgi9hYJwjl" title="Expected volatility, maximum">115.81</span></td><td>%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expected life (in years)</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MinimumMember_zGpXIOk4ppd5" title="Expected life (in years)">9.0</span> to <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MaximumMember_zaFw0FFl5sB9" title="Expected life (in years)">10.0</span></td><td> </td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_zhdQGbCdgbjf" title="Expected life (in years)">9.0</span> to <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zSjNCFC6MYQi" title="Expected life (in years)">10.0</span></td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Expected dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250930_zfV2CTTJJrB5" style="width: 16%; text-align: right" title="Expected dividend yield">0.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930_zwOmV0SC33ld" style="width: 16%; text-align: right" title="Expected dividend yield">0.0</td><td style="width: 1%; text-align: left">%</td> </tr> </table> <p id="xdx_8A4_zk2ZTK6E2uF8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatilities utilized in the model are based on historical volatility of the Company’s stock price. The risk-free interest rate is derived from values assigned to U.S. Treasury bonds with terms that approximate the expected option lives in effect at the time of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 131334 264667 24986 235509 133333 264667 100000 400000 29000 200000 100000 200000 <p id="xdx_890_ecustom--SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock_znP3H8jszU0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of stock option awards and restricted stock grants, inclusive of awards granted under the 2018 Stock Plan and Inducement Option Grants for the nine months ended September 30, 2025 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zm9XqMwh7guf" style="display: none">Schedule of Stock Options Awards and Restricted Stock Grants</span></span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restricted Stock Awards</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-vested</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in years)</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Equity awards outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEjNk7MRoiYk" style="width: 8%; text-align: right" title="Options outstanding, beginning balance">107,865</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYSvnFk0dPB3" style="width: 8%; text-align: right" title="Weighted average exercise price, beginning balance">28.97</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDigw3GaAqd4" style="width: 8%; text-align: right" title="Non-vested stock awards, beginning balance">2,647</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhfqZXKQw2Cl" style="width: 8%; text-align: right" title="Weighted average grant date fair value, beginning balance">14.85</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Equity awards granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z13XqfESFrnd" style="text-align: right" title="Options outstanding, granted">35,693</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zehXpYNUcGMh" style="text-align: right" title="Weighted average exercise price, granted">11.44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zATV9qpMJ077" style="text-align: right" title="Non-vested stock awards, granted"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFEkLAxARoS3" style="text-align: right" title="Weighted average grant date fair value, granted"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Equity awards issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssued_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbk6ClH3a3uj" style="text-align: right" title="Options outstanding, issued"><span style="-sec-ix-hidden: xdx2ixbrl0935">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionIssuedWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1hAKgvbZTQb" style="text-align: right" title="Weighted average exercise price, issued"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssued_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1S0DY3g6Mxc" style="text-align: right" title="Non-vested stock awards, issued">2,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageGrantDateFairValue_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYu7HX23Ltq9" style="text-align: right" title="Weighted average grant date fair value, issued">14.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Equity awards terminated or forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEKSWJtTaGP8" style="border-bottom: Black 1pt solid; text-align: right" title="Equity awards terminated or forfeited">(118,572</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zraznAyN1oii" style="padding-bottom: 1pt; text-align: right" title="Equity awards terminated or forfeited">25.56</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOeZtpYKtcGd" style="border-bottom: Black 1pt solid; text-align: right" title="Non-vested stock awards, Terminated"><span style="-sec-ix-hidden: xdx2ixbrl0947">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziOFVr5taCPf" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, Terminated or forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0949">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Equity awards outstanding at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgmpWgYmMied" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending balance">24,986</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm0l9ED4cA6b" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, ending balance">20.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zObtNvP9wFJb" style="border-bottom: Black 2.5pt double; text-align: right" title="Non-vested stock awards, ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLPm7IWvjCJ2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgtpUGQwTPNa" title="Weighted average contractual terms">8.8</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Equity awards exercisable at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8untn9LNRa" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, exercisable">17,292</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zStYACzEd35d" style="text-align: right" title="Weighted average exercise price, exercisable">24.85</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znHd6sgVrWl1" title="Weighted average contractual terms, exercisable">8.4</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Aggregate intrinsic value of equity awards exercisable at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTUXoHB74fzg" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, aggregate intrinsic value, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0967">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 107865 28.97 2647 14.85 35693 11.44 2647 14.85 118572 25.56 24986 20.12 P8Y9M18D 17292 24.85 P8Y4M24D 58000 P3Y P4Y 11.44 <p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zPNW65GRsDqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from the Company’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate. The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zpVXNLFJJ91b" style="display: none">Schedule of Assumptions Used to Determine Fair Value of Options Granted</span></span></span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Risk-free interest rate</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20250930_zLumz3kqlcm5" title="Risk-free interest rate, minimum">4.22</span> to <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20250930_zPRtt4JLCSF" title="Risk-free interest rate, maximum">4.55</span></td><td>%</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20240930_zm1Ype340Jek" title="Risk-free interest rate, minimum">3.72</span> to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20240101__20240930_z65lDjcgugo8" title="Risk-free interest rate, maximum">4.31</span></td><td>%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected volatility</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250101__20250930_zvMs1K2yQJTk" title="Expected volatility, minimum">110.74</span> to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250101__20250930_zHL982cXr88b" title="Expected volatility, maximum">123.22</span></td><td>%</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20240930_zSrFGvebFBib" title="Expected volatility, minimum">101.74</span> to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20240101__20240930_zZbgi9hYJwjl" title="Expected volatility, maximum">115.81</span></td><td>%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expected life (in years)</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MinimumMember_zGpXIOk4ppd5" title="Expected life (in years)">9.0</span> to <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250930__srt--RangeAxis__srt--MaximumMember_zaFw0FFl5sB9" title="Expected life (in years)">10.0</span></td><td> </td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_zhdQGbCdgbjf" title="Expected life (in years)">9.0</span> to <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zSjNCFC6MYQi" title="Expected life (in years)">10.0</span></td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Expected dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250930_zfV2CTTJJrB5" style="width: 16%; text-align: right" title="Expected dividend yield">0.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930_zwOmV0SC33ld" style="width: 16%; text-align: right" title="Expected dividend yield">0.0</td><td style="width: 1%; text-align: left">%</td> </tr> </table> 0.0422 0.0455 0.0372 0.0431 1.1074 1.2322 1.0174 1.1581 P9Y P10Y P9Y P10Y 0.000 0.000 <p id="xdx_800_ecustom--WarrantsTextBlock_zMRjNkTOCpF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9. <span id="xdx_82F_zRap0Sz3okvh">Warrants </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z8JWUhp2FUNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of all warrant activity for the nine-month period ended September 30, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zotYBiUG8aLh" style="display: none">Schedule of Warrant Activity</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Warrants</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issued</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20250930_zLuELJIaUtMl" style="width: 16%; text-align: right" title="Number of Warrants Issued, Warrants outstanding, Beginning balance">395,224</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930_ziv1uI9zqMc9" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Beginning balance">32.74</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20250930_zMIkQAYivCz" style="text-align: right" title="Number of Warrants Issued, Warrants issued">1,475,838</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodsWeightedAverageExercisePriceWarrantsIssued_c20250101__20250930_zACIjmWhApC2" style="text-align: right" title="Weighted Average Exercise Price, Warrants issued">4.54</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants exercised – cashless</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisedCashless_c20250101__20250930_zaYEUFNnCpdj" style="text-align: right" title="Number of Warrants Issued, Warrants exercised cashless">(223,946</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodsWeightedAverageExercisePriceWarrantsExercisedCashless_c20250101__20250930_zRWA7ft6OO65" style="text-align: right" title="Weighted Average Exercise Price, Warrants exercised cashless"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20250101__20250930_zDfFT4uCQ5vc" style="text-align: right" title="Number of Warrants Issued, Warrants exercised">(671,732</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodsWeightedAverageExercisePriceWarrantsExercised_c20250101__20250930_zoe2GfRrGrrc" style="text-align: right" title="Weighted Average Exercise Price, Warrants exercised">5.16</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Warrants expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20250101__20250930_zro1hCfW8bK3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Issued, Warrants expired">(10,137</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250930_zRbj7GSlPxt5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Warrants expired">242.61</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Warrants outstanding at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20250930_zO8DLhxIjEOj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Issued, Warrants outstanding, Ending balance">965,247</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250930_zr06MB8nJ703" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Ending balance">8.18</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Aggregate intrinsic value of outstanding warrants at September 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iI_pp0p0_c20250930_zy2NfhmwWIEl" title="Aggregate intrinsic value of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl1035">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average remaining contractual terms at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_z23uMRFZP4kj" title="Weighted average remaining contractual terms">2.8</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A1_zpKdPDTF4Vy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z8JWUhp2FUNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of all warrant activity for the nine-month period ended September 30, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zotYBiUG8aLh" style="display: none">Schedule of Warrant Activity</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Warrants</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issued</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20250930_zLuELJIaUtMl" style="width: 16%; text-align: right" title="Number of Warrants Issued, Warrants outstanding, Beginning balance">395,224</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930_ziv1uI9zqMc9" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Beginning balance">32.74</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20250930_zMIkQAYivCz" style="text-align: right" title="Number of Warrants Issued, Warrants issued">1,475,838</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodsWeightedAverageExercisePriceWarrantsIssued_c20250101__20250930_zACIjmWhApC2" style="text-align: right" title="Weighted Average Exercise Price, Warrants issued">4.54</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants exercised – cashless</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisedCashless_c20250101__20250930_zaYEUFNnCpdj" style="text-align: right" title="Number of Warrants Issued, Warrants exercised cashless">(223,946</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodsWeightedAverageExercisePriceWarrantsExercisedCashless_c20250101__20250930_zRWA7ft6OO65" style="text-align: right" title="Weighted Average Exercise Price, Warrants exercised cashless"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20250101__20250930_zDfFT4uCQ5vc" style="text-align: right" title="Number of Warrants Issued, Warrants exercised">(671,732</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriodsWeightedAverageExercisePriceWarrantsExercised_c20250101__20250930_zoe2GfRrGrrc" style="text-align: right" title="Weighted Average Exercise Price, Warrants exercised">5.16</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Warrants expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20250101__20250930_zro1hCfW8bK3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Issued, Warrants expired">(10,137</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250930_zRbj7GSlPxt5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Warrants expired">242.61</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Warrants outstanding at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20250930_zO8DLhxIjEOj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Issued, Warrants outstanding, Ending balance">965,247</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250930_zr06MB8nJ703" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Ending balance">8.18</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Aggregate intrinsic value of outstanding warrants at September 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iI_pp0p0_c20250930_zy2NfhmwWIEl" title="Aggregate intrinsic value of outstanding warrants"><span style="-sec-ix-hidden: xdx2ixbrl1035">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average remaining contractual terms at September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930_z23uMRFZP4kj" title="Weighted average remaining contractual terms">2.8</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> 395224 32.74 1475838 4.54 -223946 671732 5.16 10137 242.61 965247 8.18 P2Y9M18D <p id="xdx_809_eus-gaap--LesseeOperatingLeasesTextBlock_z1XA6LUeX8cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10. <span id="xdx_829_zPrp5anqwzoe">Leases</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrenceville, New Jersey Lease</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2023, the Company renewed its Lawrenceville office lease for a <span id="xdx_902_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20230831__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember_zI4RzHQjOKVg" title="Operating lease, term">24</span>-month agreement for <span id="xdx_90E_eus-gaap--AreaOfLand_iI_pp0p0_usqrt_c20230831__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember_zbpyA9M6EcT2" title="Area of land">9,850</span> square feet with monthly rent payments of approximately $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20230801__20230831__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember__srt--RangeAxis__srt--MinimumMember_zLtj1enJ5Vwk" title="Payments for rent">22,983</span> to $<span id="xdx_90C_eus-gaap--PaymentsForRent_pp0p0_c20230801__20230831__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember__srt--RangeAxis__srt--MaximumMember_zqLOaibUjy1i" title="Payments for rent">23,394</span>. In April 2025, the Company renewed its Lawrenceville office lease until November 30, 2028 for <span id="xdx_905_eus-gaap--AreaOfLand_iI_pp0p0_usqrt_c20250430__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember_zMb5L83bFNIg" title="Area of land">4,359</span> square feet (to be reduced to <span id="xdx_90C_eus-gaap--AreaOfLand_iI_pp0p0_usqrt_c20260401__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zeoxXxBPqLtj" title="Area of land">4,011</span> following April 1, 2026) with monthly rent payments of approximately $<span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20250401__20250430__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember__srt--RangeAxis__srt--MinimumMember_zyPsq6yBycSf" title="Payments for rent">10,361</span> to $<span id="xdx_90B_eus-gaap--PaymentsForRent_pp0p0_c20250401__20250430__us-gaap--TypeOfArrangementAxis__custom--LawrencevilleNewJerseyLeaseMember__srt--RangeAxis__srt--MaximumMember_z6rMaI9A4Bhl" title="Payments for rent">10,863</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Huntsville, Alabama Lease</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2023, the Company renewed its Huntsville facility lease for a <span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20230131__us-gaap--TypeOfArrangementAxis__custom--HuntsvilleAlabamaLeaseMember_zz0ErMxiHM32" title="Operating lease, term">60</span>-month lease agreement for <span id="xdx_905_eus-gaap--AreaOfLand_iI_pp0p0_usqrt_c20230131__us-gaap--TypeOfArrangementAxis__custom--HuntsvilleAlabamaLeaseMember_zYrhn9KkgC2a" title="Area of land">11,420</span> square feet with monthly rent payments of approximately $<span id="xdx_90B_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230131__us-gaap--TypeOfArrangementAxis__custom--HuntsvilleAlabamaLeaseMember__srt--RangeAxis__srt--MinimumMember_zrWl6r7LJDFg" title="Payments for rent">28,550</span> to $<span id="xdx_90D_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230131__us-gaap--TypeOfArrangementAxis__custom--HuntsvilleAlabamaLeaseMember__srt--RangeAxis__srt--MaximumMember_zLbysAMK17Pa" title="Payments for rent">30,903</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zokGMC7YlAU7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a table of the lease payments and maturity of the Company’s operating lease liabilities as of September 30, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zUgsbPbDjiJ" style="display: none">Schedule of Lease Payments and Maturity of Operating Lease Liabilities</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_49E_20250930_zZcZoS96puh4" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzy9p_zlxHnzFTHcX" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">120,196</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzy9p_zDtWnBcM9ZD6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">488,821</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzy9p_zmQaGLzxUgD4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">498,086</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzy9p_zUlWHcoRmi0e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2028 </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">149,896</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzy9p_maOLLz45C_maOLLzlbh_zAdzn60BN9tg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Subtotal future lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,256,999</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zTC0Rg4oVxSi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(154,767</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_zJiIzM82Ec5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,102,232</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average remaining life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250930_zeFzq5mInAJj" title="Operating lease, weighted average remaining lease term">2.6</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20250930_zwhhwNEred27" style="text-align: right" title="Operating lease, weighted average discount rate, percent">9.98</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AB_zhRemZ2nROf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine-month period ended September 30, 2025, operating lease expense was $<span id="xdx_901_eus-gaap--OperatingLeaseCost_pp0p0_c20250101__20250930_zNfN28S6y49h" title="Operating lease, cost">402,384</span> and cash paid for operating leases included in operating cash flows was $<span id="xdx_90E_eus-gaap--OperatingLeasePayments_pp0p0_c20250101__20250930_zRorZuOYk8dh" title="Operating lease, payments">400,936</span>. For the nine-month period ended September 30, 2024, operating lease expense was $<span id="xdx_903_eus-gaap--OperatingLeaseCost_pp0p0_c20240101__20240930_zJYjEsf900J9" title="Operating lease, cost">479,401</span> and cash paid for operating leases included in operating cash flows was $<span id="xdx_907_eus-gaap--OperatingLeasePayments_pp0p0_c20240101__20240930_zaqDFKynrFB2" title="Operating lease, payments">488,047</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P24M 9850 22983 23394 4359 4011 10361 10863 P60M 11420 28550 30903 <p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zokGMC7YlAU7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a table of the lease payments and maturity of the Company’s operating lease liabilities as of September 30, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zUgsbPbDjiJ" style="display: none">Schedule of Lease Payments and Maturity of Operating Lease Liabilities</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_49E_20250930_zZcZoS96puh4" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzy9p_zlxHnzFTHcX" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">120,196</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzy9p_zDtWnBcM9ZD6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">488,821</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzy9p_zmQaGLzxUgD4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">498,086</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzy9p_zUlWHcoRmi0e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2028 </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">149,896</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzy9p_maOLLz45C_maOLLzlbh_zAdzn60BN9tg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Subtotal future lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,256,999</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zTC0Rg4oVxSi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(154,767</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_zJiIzM82Ec5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,102,232</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average remaining life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250930_zeFzq5mInAJj" title="Operating lease, weighted average remaining lease term">2.6</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average discount rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20250930_zwhhwNEred27" style="text-align: right" title="Operating lease, weighted average discount rate, percent">9.98</td><td style="text-align: left">%</td></tr> </table> 120196 488821 498086 149896 1256999 154767 1102232 P2Y7M6D 0.0998 402384 400936 479401 488047 <p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zAQ4HA9yiRB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11. <span id="xdx_825_zP3Olyk4fmD2">Commitments and Contingencies</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is not currently a party to any material legal proceedings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zSUBefvy1Pug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12. <span id="xdx_82C_zwAEzVkuiGLf">Subsequent Events</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated its subsequent events from September 30, 2025, through the date these condensed consolidated financial statements were issued.</span></p> false false false false false false